2-Azabicyclo<3.2.2>nonan | 283-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 2-Azabicyclo<3.2.2>nonan
• 英文别名: 2-azabicyclo [3.2.2]nonane；2-Azabicyclo[3.2.2]nonane
• CAS: 283-21-6
• 化学式: C₈H₁₅N
• mdl: MFCD19219314
• 分子量: 125.214
• InChiKey: NGERQMAWGVKQNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Azabicyclo<3.2.2>nonan 、 (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-4-(3-methylsulfonyloxypropyl)piperazine 在 盐酸 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2R)-4-[3-(3-azabicyclo[3.2.2]non-3-yl)propyl]-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)piperazine dihydrochloride
  参考文献：
  名称：

  Piperazine derivatives as tachykinin antagonists

  摘要：

  这个申请是PCT/JP96/03641的371文件，提交日期为1996年12月12日。

  公开号：

  US06087357A1

文献信息

• Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives
  申请人：University of Graz

  公开号：EP2301627A1

  公开（公告）日：2011-03-30

  The present invention relates to novel 3-azabicyclo[3.2.2]nonane derivatives of the general formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification. The novel 3-azabicyclo[3.2.2]nonane derivatives are particularly useful for treatment and prevention of malaria and trypanosomiasis.

  本发明涉及一般式(I)的新型3-氮杂双环[3.2.2]壬烷衍生物 或其药学上可接受的盐 其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义。这些新型3-氮杂双环[3.2.2]壬烷衍生物特别适用于治疗和预防疟疾和锥虫病。
• [EN] NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS DE 1,4-DIAZA-BICYCLO[3.2.2]NONYLOXADIAZOLYLE UTILES EN TANT QUE MODULATEURS DE RÉCEPTEURS D'ACÉTYLCHOLINE NICOTINIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2009112460A1

  公开（公告）日：2009-09-17

  This invention relates to novel N-oxides of a 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivative and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及一种新颖的1,4-二氮杂双环[3.2.2]壬基噁二唑衍生物的N-氧化物及其在制备药物组合物中的应用。该发明的化合物被发现是胆碱能受体的胆碱能配体。由于它们的药理特性，该发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病或紊乱、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状等多种疾病或紊乱有用。
• [EN] CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR<br/>[FR] DÉRIVÉS CONDENSÉS D'AZINE POUR LE TRAITEMENT DE MALADIES LIÉES AUX RÉCEPTEURS DE L'ACÉTYLCHOLINE
  申请人：ORGANON NV

  公开号：WO2011045258A1

  公开（公告）日：2011-04-21

  The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by nicotinic acetylcholine receptors, such as schizophrenia and Alzheimer's disease.

  本发明涉及式(I)的杂环衍生物，其中变量如规范中所定义，或其药用可接受盐或溶剂。本发明还涉及包含所述杂环衍生物的药物组合物，以及它们在治疗中的应用，例如在治疗或预防由尼古丁乙酰胆碱受体介导的疾病，如精神分裂症和阿尔茨海默病。
• UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
  申请人：KALLUS Christopher

  公开号：US20100035930A1

  公开（公告）日：2010-02-11

  The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

  这项发明涉及到本处定义的公式I的化合物，这些化合物是活化的凝血酶可激活纤溶抑制剂的抑制剂。公式I的化合物适用于制造用于预防、次级预防和治疗与血栓形成、栓塞、高凝状态或纤维变化相关的一个或多个疾病的药物。
• [EN] PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES<br/>[FR] COMPOSÉS DE PYRIMIDINE-2-AMINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES KINASES JAK
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2009103032A1

  公开（公告）日：2009-08-20

  This invention is directed to compounds of formula (I): where, n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

  这项发明涉及式(I)的化合物：其中，n、m、Y、R1、R2、R3、R4和R5如本文所披露，作为分离的立体异构体或其混合物，或其药学上可接受的盐；包括式(I)化合物的药物组合物；以及使用这些化合物和药物组合物治疗与JAK2活性相关的疾病或症状的方法。